Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: Economic analysis from NHS Sentinel Sites Study

BMJ (Online)

Volumn 345, Issue 7882, 2012, Pages

  Legood, Rosa ^a   Smith, Megan ^b   Lew, Jie Bin ^b   Walker, Robert ^b   Moss, Sue ^c   Kitchener, Henry ^d   Patnick, Julietta ^e   Canfell, Karen ^b,f  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b CANCER RESEARCH DIVISION   (Australia)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e NATIONAL HEALTH SERVICE   (United Kingdom)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; HIDDEN MARKOV MODEL; HUMAN; HUMAN PAPILLOMAVIRUS TEST; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT CANCER; SENSITIVITY ANALYSIS; SERODIAGNOSIS; UNITED KINGDOM; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRUS INFECTIONS; PATIENT COMPLIANCE; SENTINEL SURVEILLANCE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

EID: 84868694601     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e7086     Document Type: Article

References (30)

1. Luesley D, Leeson S, eds. Colposcopy and programme management: guidelines for the NHS cervical screening programme. NHS Cancer Screening Programmes, 2004.
2. Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB. HPV testing as an adjunct to cytology follow-up of women treated for cervical intraepithelial neoplasia. BJOG 2008;115:1001-7. (Pubitemid 351841763)
3. Kelly RS, Patnick J, Kitchener HC, Moss SM, for the NHSCSP HPV Special Interest Group. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites Study. Br J Cancer 2011;105:983-8.
4. Coupe VM, Berkhof J, Verheijen RH, Meijer CJ. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG 2007;114:416-24. (Pubitemid 46393302)
5. Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, et al. Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol 2010;166:1158-70.
6. National Institute for Health and Clinical Excellence. Guide to methods of health technology appraisal. NICE, 2008.
7. Curtis L. Unit costs of health and social care. Personal Social Services Research Unit, University of Kent, 2010.
8. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004;30:205-11. (Pubitemid 38418058)
9. Canfell K, Barnabas R, Beral V, Patnick J. The predicted effect of changes in cervical screening practice. Br J Cancer 2004;91:530-6.
10. Human papillomavirus triage test for women with possible of definite low-grade squamous intrapeithelial lesions. Medical Services Advisory Committee, 2009. (MSAC reference 39).
11. Automation assisted and liquid based cytology for cervical cancer screening. Medical Services Advisory Committee, 2009. (MSAC reference 1122.)
12. Creighton P, Lew J, Clements M, Smith M, Howard K, Dyer S, et al. Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health 2010;10:734.
13. Cecchini S, Visioli C, Zappa M, Ciatto S. Recurrence after treatment by loop electrosurgical excision procedure (LEEP) of high-grade cervical intraepithelial neoplasia. Tumori 2002;88:478-80. (Pubitemid 36193897)
14. Flannelly G, Langhan H, Jandial L, Mana E, Campbell M, Kitchener H. A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. BJOG 1997;104:718-22. (Pubitemid 27278356)
15. .Rema P, Suchetha S, Thara S, Sebastian P, Wesley MD, Sankaranarayanan R. Effectiveness, acceptability and safety of LEEP in Kerala, India: beginners' experience. 2007. http://screening.iarc.fr/poster/Effectiveness, %20acceptability%20and%20safety%20of%20LEEP%20in%20Kerala, %20India%20beginners%20experience.pdf.
16. Strander B, Andersson-Ellström A, Milsom I, Sparén P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007;335:1077.
17. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst 2009;101:721-8.
18. Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349:978-80. (Pubitemid 27149800)
19. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006;118:2048-55.
20. Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol 2009;200:422.e1-9.
21. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust 2006;185:482-6. (Pubitemid 44767075)
22. Health and Social Care Information Centre. Cervical screening programme, England 2007-2008. Health and Social Care Information Centre, 2008.
23. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(suppl 3):S3/78-89.
24. National Screening Unit. Guidelines for cervical screening in New Zealand. National Screening Unit, Ministry of Health, 2008 (available at www.nsu.govt.nz/files/NCSP/NCSP-Guidelines-ALL-small(1).pdf).
25. National Cervical Screening Program. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities. National Health and Medical Research Council, 2005 (available at www.nhmrc.gov.au/-files-nhmrc/publications/attachments/wh39.pdf).
26. Dillner J, Reboli M, Birembaut P, Petry K-U, Szarewki A, Munk C. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
27. Cruikshank M, Hadwin R, Nelson L, Walker P, Moore C, Kitchener K. HPV test of cure: effective protection for five years. International Papillomavirus Conference, Berlin, Germany, 2011.
28. Moss S, Gray A, Marteau T, Legood R, Henstock E, Masissi E. Evaluation of HPV/LBC cervical screening pilot studies: summary of report to the Department of Health. NHS Cervical Screening Programme, 2004.
29. Martin-Hirsch P, Rash B, Martin A, Standaert B. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales. Br J Obstet Gynaecol 2007;114:408-15. (Pubitemid 46393298)
30. Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer 2004;91:84-91. (Pubitemid 39013049)